Title: A 9#gene expression signature to predict stage development in resectable stomach
adenocarcinoma
Version: 6 Date: 19 Jul 2022
Reviewer's report:
Liu et al. identified a 9-gene signature to predict cancer stage in STAD. Different datasets and
methods were used to validate the results. Overall, manuscript is well written and analysis is
rigorous. I have few concerns that should be addressed in the manuscript.
(1) Please elaborate abbreviations on their first appearance in the manuscript, Example: AJCC,
TNM.
(2) “There are chances to link the gene expression profile.” Incomplete statement.
(3) There are some sentences which are not clear. Ex: Considerable understaging still occurs “.
Authors are advised to proofread the manuscript with native English speaker.
(4) Introduction lacks detailed information on association of genes with STAD prognosis/
survival. There are numerous studies which used gene signatures to predict prognosis or survival.
Authors must provide clear and detail information on what are the previous studies that identified
gene signature to predict prognosis in STAD and describe the novelty and advancements of this
study.
(5) Generally, the grouping of stages would be early and later stages.
(6) “The present study aimed to perform …. based on bioinformatic algorithms”. What is
bioinformatics algorithm?
(7) In the methods, what is T stage information? What is the criteria to divide the patients into
low and high-stage groups? What about stage IV? Why stage IIb is under high-stage group while
IIa under low-stage group?
(8) Perform the gene expression difference between stage IIa and IIb. Are they significant?
(9) Why the data was split into 66.7% and 33.3% for training and validation. Usually, data is
split into 5:5 or 6:4 or 7:3 or 8:2 etc. Please define training-validation set.
Title: A 9#gene expression signature to predict stage development in resectable stomach
adenocarcinoma
Version: 6 Date: 19 Jul 2022
Reviewer's report:
Liu et al. identified a 9-gene signature to predict cancer stage in STAD. Different datasets and
methods were used to validate the results. Overall, manuscript is well written and analysis is
rigorous. I have few concerns that should be addressed in the manuscript.
(1) Please elaborate abbreviations on their first appearance in the manuscript, Example: AJCC,
TNM.
(2) “There are chances to link the gene expression profile.” Incomplete statement.
(3) There are some sentences which are not clear. Ex: Considerable understaging still occurs “.
Authors are advised to proofread the manuscript with native English speaker.
(4) Introduction lacks detailed information on association of genes with STAD prognosis/
survival. There are numerous studies which used gene signatures to predict prognosis or survival.
Authors must provide clear and detail information on what are the previous studies that identified
gene signature to predict prognosis in STAD and describe the novelty and advancements of this
study.
(5) Generally, the grouping of stages would be early and later stages.
(6) “The present study aimed to perform …. based on bioinformatic algorithms”. What is
bioinformatics algorithm?
(7) In the methods, what is T stage information? What is the criteria to divide the patients into
low and high-stage groups? What about stage IV? Why stage IIb is under high-stage group while
IIa under low-stage group?
(8) Perform the gene expression difference between stage IIa and IIb. Are they significant?
(9) Why the data was split into 66.7% and 33.3% for training and validation. Usually, data is
split into 5:5 or 6:4 or 7:3 or 8:2 etc. Please define training-validation set.
Please review this paper.
user
Title: A 9#gene expression signature to predict stage development in resectable stomach
adenocarcinoma
Version: 6 Date: 19 Jul 2022
Reviewer's report:
Liu et al. identified a 9-gene signature to predict cancer stage in STAD. Different datasets and
methods were used to validate the results. Overall, manuscript is well written and analysis is
rigorous. I have few concerns that should be addressed in the manuscript.
(1) Please elaborate abbreviations on their first appearance in the manuscript, Example: AJCC,
TNM.
(2) “There are chances to link the gene expression profile.” Incomplete statement.
(3) There are some sentences which are not clear. Ex: Considerable understaging still occurs “.
Authors are advised to proofread the manuscript with native English speaker.
(4) Introduction lacks detailed information on association of genes with STAD prognosis/
survival. There are numerous studies which used gene signatures to predict prognosis or survival.
Authors must provide clear and detail information on what are the previous studies that identified
gene signature to predict prognosis in STAD and describe the novelty and advancements of this
study.
(5) Generally, the grouping of stages would be early and later stages.
(6) “The present study aimed to perform …. based on bioinformatic algorithms”. What is
bioinformatics algorithm?
(7) In the methods, what is T stage information? What is the criteria to divide the patients into
low and high-stage groups? What about stage IV? Why stage IIb is under high-stage group while
IIa under low-stage group?
(8) Perform the gene expression difference between stage IIa and IIb. Are they significant?
(9) Why the data was split into 66.7% and 33.3% for training and validation. Usually, data is
split into 5:5 or 6:4 or 7:3 or 8:2 etc. Please define training-validation set.
assistant